Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes Patients

BACKGROUND: Diabetic kidney disease (DKD) is the primary cause of end-stage renal disease, raising a considerable burden worldwide. Recognizing novel biomarkers by metabolomics can shed light on new biochemical insight to benefit DKD diagnostics and therapeutics. We hypothesized that serum metabolit...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xiaofeng, Wang, Xiaoyi, Shao, Xue, Wang, Yucheng, Feng, Shi, Wang, Cuili, Ye, Cunqi, Chen, Jianghua, Jiang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126316/
https://www.ncbi.nlm.nih.gov/pubmed/35615098
http://dx.doi.org/10.3389/fmed.2022.819311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126316/
https://www.ncbi.nlm.nih.gov/pubmed/35615098
http://dx.doi.org/10.3389/fmed.2022.819311

Ejemplares similares